Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395018 · ClinicalTrials.gov registry record · Phase 3
Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 109
- Enrollment target
NCT00395018 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 109 participants.
The verdict
NCT00395018, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.
Interventions
- DRUG entecavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395018
The ClinicalTrials.gov registry entry for NCT00395018 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which entecavir is the first listed.
NCT00395018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395018 about?
NCT00395018 is a clinical study titled "Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection". The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.
What is the current status of trial NCT00395018?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 109 participants. The study started on 2007-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00395018?
The interventions under investigation include: entecavir (DRUG).
Who is sponsoring clinical trial NCT00395018?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.